Featured Resources
-
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
Case study
Catch up on our ADC development series on YouTube to hear more expert insights.
Antibody-drug conjugates (ADCs) represent an important approach to targeted cancer therapy, combining the specificity of antibodies with the potent cytotoxicity of small-molecule drugs. Despite their promise, clinical ADC development has faced numerous challenges, including limited therapeutic windows and off-target toxicity. To address these challenges, we’re rethinking traditional approaches, and new ADC development is shifting its focus from antibody-centric to payload-centric strategies.
A Holistic Approach to ADC Development
Historically, ADC development has largely centered around optimizing the antibody component and subsequently conjugating a cytotoxic payload/linker combination. The assumption was that the specificity of the antibody would allow selective delivery of the payload and this would translate directly to clinical tolerability. While crucial, this focus has often overshadowed other equally important aspects, such as conjugation site and technique, sample heterogeneity, linker stability and, more recently, payload selection.
A holistic approach to ADC development recognizes the need to balance all components—antibody, conjugation, linker, and payload—to create a more effective and safer therapeutic agent. This involves refining antibody specificity and minimizing the biophysical impact of conjugation, while also designing linkers that are stable in circulation and facilitate efficient payload release at the disease site. And by optimizing how the linker is conjugated, we can enhance drug-to-antibody ratios (DARs) and sample homogeneity, ultimately improving the overall ADC therapeutic profile.
A Shift from Antibody-Centric to Payload-Centric Thinking
While ADC research traditionally focussed on the antibody, recent insights indicate that the payload plays an equally crucial role in determining the efficacy and safety of ADCs. As these therapeutics evolve, we are witnessing a move from traditional cytotoxic payloads toward more mechanistically targeted agents with defined, specific modes of action, tailored toward certain patient populations. Indeed, in oncology, payload selection is becoming more meticulously aligned with the cancer type and disease context, ensuring maximum therapeutic impact with minimal collateral damage.
Furthermore, a robust understanding of how the payload interacts with cellular mechanisms delivers a second level of selectivity and can also inform better decisions in linker design, conjugation chemistry, and dose optimization. This paradigm shift emphasizes the importance of selecting potent and targeted agents that are effective at low doses and aligned with the intended patient population.
Key Takeaways
Incorporating a holistic and payload-centric perspective in new ADC development not only broadens therapeutic possibilities but also addresses the limitations seen in earlier generations of ADCs. By evolving from an antibody-centric mindset, we are becoming better positioned to harness the full potential of ADC technology—offering hope for more precise and effective treatments, for cancer and other diseases, in the future.
Learn more about Sygnature’s ADC capabilities here.
Catch up on the full ADC development blog series:
Part 2: What’s the Evolving Role of Medicinal Chemistry in ADC Development?
Part 3: Linker Technologies in ADCs: How They Impact Efficacy & Stability
Part 4: Toxicity & Efficacy in ADCs: How to Get it Right
Part 5: 3 Transformative Changes in ADC Development Over the Next Decade
About the Authors
Dr. Allan Jordan is Vice President of Oncology Drug Discovery at Sygnature Discovery. He delivers broad scientific oversight and mentorship of all Sygnature’s oncology projects, alongside alternate modalities such as ADCs, degraders, molecular glues and Direct-to-Biology approaches. A medicinal chemist with 25+ years’ experience in drug discovery, he has actively participated in the delivery of twenty pre-clinical candidates, of which ten have already entered human clinical trials.
Dr. Joshua Greally is ADC Discovery Consultant at Sygnature Discovery. With a foundation in medicinal chemistry, bioconjugation and ADC discovery, he guides the strategic design of next-generation antibody-drug conjugates. He specializes in taking a holistic approach to ADC development, matching antigen biology with novel payloads to overcome clinical tolerability issues and enhance targeted delivery mechanisms. Ultimately helping to bridge the gap between early discovery and successful IND submission.
FAQs
An antibody-drug conjugate is a targeted therapy that links a monoclonal antibody to a potent small molecule drug via a chemical linker. The antibody binds an antigen on the target cell and, after internalisation, delivers the payload directly to it, aiming to combine the selectivity of a biologic with the potency of a small molecule.
An ADC has four design elements: the antibody, which provides targeting; the payload, the small molecule drug that delivers the therapeutic effect; the linker, which attaches payload to antibody and controls release; and the conjugation method, which determines where and how many payloads are attached. To maximise therapeutic benefit, all four have to be balanced together.
Payload-centric development treats the payload as an essential design variable in its own right rather than a fixed cytotoxic agent bolted onto an optimized antibody. It means selecting or designing payloads with defined mechanisms, tuned pharmacokinetics and disease-specific relevance, and then optimizing linker and conjugation to maximise their therapeutic potential.
ADCs relied almost entirely on the antibody for selectivity, paired with highly potent (but non-selective) cytotoxic payloads that act on mechanisms also present in healthy cells. Challenges such as premature payload release, heterogeneous conjugation and antigen expression on normal tissue all narrowed the gap between an effective dose and a toxic one.
A holistic approach optimizes all four components of an ADC together: antibody specificity, conjugation site and homogeneity, linker stability and release, and payload mechanism and properties. It treats the ADC as a carefully tailored construct, rather than simply an antibody with a drug attached.
This is Part 1 of our five-part ADC development blog series. Follow the series, or catch up with Allan Jordan and Joshua Greally on our YouTube channel. To discuss your ADC project, get in touch with the team.
